ArticleESMO real world data and digital oncology2025
Real-world treatment patterns and survival in patients with synchronous and metachronous metastatic colorectal cancer in the Netherlands.
Article in ESMO real world data and digital oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Danish randomized trial of trifluridine-tipiracil and bevacizumab in metastatic colorectal cancer: final survival andESMO gastrointestinal oncology · 2026Article
- Outcomes and management of primary tumors in metastatic MSI/dMMR colorectal cancer patients treated with immune checkpoint inhibitors: a cohort study.ESMO gastrointestinal oncology · 2026Article
- Article
- The role of brachytherapy in liver metastases from colorectal cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Insight into real-world treatment patterns in daily practice of patients with metastatic colorectal cancer (mCRC) is limited. Aim of this population-based study is to provide an overview of treatment and overall survival (OS) of patients with mCRC and to compare differences in treatment between synchronous and metachronous mCRC. Method: All patients with mCRC of whom the primary tumour was diagnosed in the first half of 2015 were selected from the Netherlands Cancer Registry. Data regarding subsequent treatments were collected in 2019. Treatment patterns were compared between patients with synchronous and metachronous mCRC. OS was analysed using the Kaplan-Meier method. Results: In total, 1532 patients with synchronous mCRC and 870 patients with metachronous mCRC were included. Patients with metachronous mCRC more often underwent local treatment of distant metastases ( Conclusions: Real-world data offer valuable insights for mCRC patients in everyday clinical practice, enabling clinicians to provide more informed guidance to their patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.